Licensed recreational cannabis is about to celebrate its very first birthday in Canada, but producers such as Canopy Development (TSX: WEED NYSE: CGC) are also nonetheless focusing on increasing networks for health-related individuals.
In an work to bring extra education initiatives on prescribing cannabis to Quebec-primarily based medical doctors, the organization just launched the cost-free Prescriber Coaching Plan in Montreal.
That system is now up and operating by way of a partnership among the Santé Cannabis clinic / research centre and Canopy’s health-related wing Spectrum Therapeutics, which is offering an educational grant to fund the initiative.
Citing a 500% enhance in requests for instruction and patient referral facts considering the fact that 2018, the Santé Cannabis clinic will supply proof-primarily based courses on building dosage remedy plans by way of self-guided modules and direct telephone help to physicians.
Canopy’s Chief Healthcare Officer Dr. Mark Ware commented on the newly-announced partnership:
A considerable situation stopping the consideration of cannabinoid medicine by healthcare experts is that the subject is not normally integrated in health-related college curriculum. We’ve invested in a variety of education initiatives to address this gap in know-how, and this new system creates an significant resource for Québec physicians.
Aside from getting licensing for a new extraction facility in Saskatoon final month and getting into an agreement to acquire Beckley Canopy Therapeutics, Canopy Development has had a fairly low important summer following disappointing quarterly income numbers.
Canopy is presently preparing for the launch of licensed vaporizer and edible goods as Wellness Canada hands down new regulations covering these solution sorts on the anniversary of the Cannabis Act going into impact.
In addition to Canadian operations, the organization not too long ago extended a distribution deal for U.S. vaporizer goods by way of Greenlane Holdings Inc (NASDAQ: GNLN). In the wake of frequent unfavorable press about suspected wellness problems from unlicensed vape goods, new regulations and bans are anticipated to arrive in the U.S. shortly on non-tobacco flavoured vape pods and oils.
Canopy’s stock is presently trading at $27.99 a share as of Monday afternoon. Even though considerably down from its $52.03 higher in April, Canopy Development is 1 of the really handful of licensed cannabis producers commanding a larger stock price tag right now than it did a month ago.